

RECEIVED
OCT 14 1999
TECH CENTER 1600/2900

Rewrite Claim 1.

1. (Amended) A method of measuring the production of a target analyte of interest in a human or animal, comprising the steps of:
- injecting [a] the human or animal with an [appropriate] amount of neutralizing targeting moiety, capable of binding specifically to the target analyte, at a concentration in excess of measurable quantities of secreted analyte;
 - allowing the targeting moiety to circulate through the injected human or animal for a time sufficient to bind to the target analyte of interest and form a targeting moiety:target analyte conjugate;
 - obtaining a sample of body fluid from the human or animal [without dissociation of the target analyte from targeting moiety];
 - combining the sample of body fluid with a capture moiety capable of binding specifically to the analyte determinants of the targeting moiety:target analyte conjugate;
 - incubating the assay mixture of step d to allow the [immobilized] capture moiety to bind specifically to [either the target analyte or the labeled targeting moiety] the targeting moiety:target analyte conjugate;
 - removing any unbound targeting moiety [and target analyte] from the capture moiety;

a'

Sub B'

- a' word. ~~sub 1~~
- g. detecting ~~[the]~~ bound targeting moiety:target analyte conjugate on the capture moiety using one or more detection labels; and
- h. determining the amount of the target analyte in the sample.

Rewrite Claim 8.

- sub C2 a2
8. (Amended) The method of claim 1, wherein the targeting moiety is selected from the group consisting of antibodies, soluble receptors, [paratopic molecules,] recombinant molecules with binding sites for the target analyte, and fragments thereof.

[Rewrite Claim 9.]

- sub 4
9. (Amended) The method of claim 8, wherein the targeting moiety is [an] a monoclonal antibody.

Rewrite Claim 12.

- a3 ~~sub 2~~
12. (Amended) The method of claim [1] 9, wherein the targeting moiety is detectably labeled through the use of a label selected from the group consisting of radioisotopes, affinity labels, enzymatic labels, and fluorescent labels.

Rewrite Claim 20.

- a4 sub C3
20. (Amended) The method of claim 8, wherein the targeting moiety is a first targeting moiety itself capable of being bound by [another molecule] a second targeting moiety.

[Rewrite Claim 21.]

21. (Amended) The method of claim 20, wherein the first targeting moiety is [an] a monoclonal antibody.

[Rewrite Claim 22.]

22. (Amended) The method of claim 21, wherein the [molecule capable of binding the targeting moiety] second targeting moiety is an antibody[which recognizes the targeting moiety].

[Rewrite Claim 23.]

23. (Amended) The method of claim 22, wherein the [antibody which recognizes the targeting moiety] second targeting moiety is a polyclonal antibody[which recognizes many epitopes on the targeting moiety].

Rewrite Claim 25.

25. (Amended) The method of claim 20, wherein the means for detecting the bound conjugate [on the solid support] is by radioimmunoassay[, wherein the molecule capable of binding the targeting moiety is labeled by linking the targeting moiety to a radioisotope].

Rewrite Claim 34.

34. (Amended) A reagent kit [useful in] for performing the method of claim

1, comprising

- a⁶
- Sub B³
D⁹
- (a) a first reagent containing a labeled targeting moiety specific for the target analyte and capable of forming a conjugate with the target analyte;
 - (b) a second reagent separated from said first reagent which contains a capture moiety for said conjugate; and
 - (c) a third reagent separated from said first and second reagents which contains a standard for the target analyte.

Rewrite Claim 37.

37. (Amended) A reagent kit [useful in] for performing the method of claim

a⁷

Sub C⁵
D¹⁰

1, comprising: (a) a first container having paratopic molecules that ^{targeting moiety} immunoreact with a target analyte, and are operatively linked to an enzyme ^{label} indicating means; (b) a second container having paratopic molecules that ^{capture moiety} immunoreact with the target analyte at a site different from the first paratopic molecules but are not in the first container; and (c) one or more other containers comprising one or more of the following: a sample reservoir, a solid phase support, wash reagents, reagents capable of detecting presence of bound antibody ^{label} from the second container, or reagents capable of amplifying the indication means.